Comparison of Single-syringe vs. Double-syringe Techniques for Adenosine Administration in PSVT

NCT07554170 | Completed Phase 4

• 1 other identifier: SVT management techniques
• Study Type: interventional
• Target: 131
• Locations: 1 country
• Sites: 2

Brief Summary

The purpose of the study is to compare the effectiveness of two different methods of administering adenosine for the treatment of stable supraventricular tachycardia (SVT).

Conditions

Supraventricular Tachycardias; Supraventricular Arrhythmia; SVT; PSVT; Supraventricular Tachycardia

Keywords

Supraventricular Tachycardia; Cardiac Arrhythmias; Cardiovascular Diseases; SVT; Single syringe; Single-syringe

Outcome Measures

Primary Outcomes (1)

• First-dose successful termination of PSVT

  Proportion of participants with conversion from paroxysmal supraventricular tachycardia to sinus rhythm after the first dose of adenosine.

  Within 2 minutes after administration of the first dose of adenosine.

Secondary Outcomes (1)

• Total administered dose of adenosine.

  From administration of the first dose until successful termination of PSVT or up to 10 minutes, whichever occurs first.

Study Arms (2)

Single-syringe technique (SST)

EXPERIMENTAL

Drug: Single-syringe Adenosine

Double-syringe technique (DST)

ACTIVE COMPARATOR

Drug: Double Syringe Adenosine

Interventions

Single-syringe Adenosine DRUG

Simplified method, containing both 6 mg of adenosine and 18 mL NS. If SVT termination failed: Second dose of adenosine with SS containing both 12 mg of adenosine and 18 mL NS. A total of three doses could be provided to each patient

Single-syringe technique (SST)

Double Syringe Adenosine DRUG

One Syringe containing 6 mg of adenosine + one syringe containing 20 mL NS aided with a stopcock. If SVT termination failed: Second dose of adenosine (12 mg) + one syringe containing 20 mL NS. A total of three doses could be provided to each

Double-syringe technique (DST)

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age 18 to 80 years
• Presentation to the emergency department with narrow-QRS tachyarrhythmia
• Heart rate ≥150 beats/min
• No visible P wave or presence of retrograde P wave on ECG
• Not responsive to Valsalva maneuvers lasting 15 to 30 seconds
• Requiring adenosine administration

You may not qualify if:

• Wide-QRS tachycardia or irregular R-R interval on ECG
• Known allergy or contraindication to adenosine
• Recent ingestion of dipyridamole, carbamazepine, or theophylline
• Caffeine ingestion within the previous 2 hours

Sponsors & Collaborators

• Hormozgan University of Medical Sciences: lead

Study Sites (2)

Shahid Mohammadi Hospital

Bandar Abbas, Hormozgan, Iran

Location

Shahid Mohammadi Hospital

Bandar Abbas, Iran

Location

MeSH Terms

Conditions

Tachycardia, Supraventricular; Arrhythmias, Cardiac; Cardiovascular Diseases

Condition Hierarchy (Ancestors)

Tachycardia; Heart Diseases; Cardiac Conduction System Disease; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Emergency Medicine Resident

Study Record Dates

• First Submitted: February 6, 2026
• First Posted: April 28, 2026
• Study Start: May 21, 2024
• Primary Completion: December 21, 2025
• Study Completion: December 21, 2025
• Last Updated: April 28, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will not share

Locations

IR (2)